Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Amirmohsen Arbabi, Xuan Bao, Wesam Shamseldin Shalaby & Reza Razeghinejad. (2022) Systemic side effects of glaucoma medications. Clinical and Experimental Optometry 105:2, pages 157-165.
Read now
Read now
Lindsay Machen, Reza Razeghinejad & Jonathan S. Myers. (2020) Fixed-combination topical anti-hypertensive ophthalmic agents. Expert Opinion on Pharmacotherapy 21:10, pages 1269-1282.
Read now
Read now
Ahmad A. Aref, Lawrence S. Geyman, Abdel-Rahman Zakieh & Humoud M. Alotaibi. (2019) Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension. Expert Review of Clinical Pharmacology 12:12, pages 1073-1079.
Read now
Read now
Jefferson D. Berryman & Gary D. Novack. (2019) Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Expert Review of Ophthalmology 14:4-5, pages 191-197.
Read now
Read now
Articles from other publishers (23)
Tyler Bahr, Scott Woolf, Hayley Favre & Corey Waldman. (2023) Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma. Canadian Journal of Ophthalmology 58:4, pages 356-360.
Crossref
Crossref
Aaron R Kaufman, Abdelrahman M Elhusseiny, Deepak P Edward, Thasarat Sutabutr Vajaranant, Ahmad A Aref & Javaneh Abbasian. (2023) Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome. European Journal of Ophthalmology, pages 112067212311596.
Crossref
Crossref
Sandy Samuel, Hani El Helwe, Cameron E. Neeson, Nathan Hall, Ryan Sameen Meshkin, Nino Odishelidze, Rebecca Ye, Ta C. Chang & David Solá-Del Valle. (2022) Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect. Journal of Ophthalmology 2022, pages 1-15.
Crossref
Crossref
Haochen Xu, Dayeong Lee, Junsang Cho, Jackson Voss, Lindsey McDaniel & Jella Angela An. (2022) Netarsudil as a Predictor of Response for MicroPulse Transscleral Laser Therapy. Ophthalmology Glaucoma 5:6, pages 658-662.
Crossref
Crossref
Maria A. Guzman Aparicio, Daniel L. Liebman, James Chodosh, Suzanne K. Freitag, Melanie Kazlas, Derek D. Mai, Catherine M. Marando, Shizuo Mukai, Annie M. Wu & Teresa C. Chen. (2022) Two pediatric cases of reticular corneal epithelial edema associated with netarsudil. American Journal of Ophthalmology Case Reports 27, pages 101638.
Crossref
Crossref
Haochen Xu, Marwa T. Thomas, Dayeong Lee, Matthew T. Hirabayashi & Jella A. An. (2022) Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study. Graefe's Archive for Clinical and Experimental Ophthalmology 260:9, pages 3001-3007.
Crossref
Crossref
Reza Kianian, Samuel W. Hulbert, Simon K. Law & JoAnn Giaconi. (2022) Effectiveness of Topical ρ-Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy. Optometry and Vision Science 99:8, pages 626-631.
Crossref
Crossref
Faraat Ali & Anam Ilyas. (2022) Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Current Research in Translational Medicine 70:3, pages 103343.
Crossref
Crossref
Susmit Mhatre, Catherine A. Opere & Somnath Singh. (2022) Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies. Journal of Controlled Release 347, pages 256-269.
Crossref
Crossref
Jo-Hsuan Wu, Sheng-Nan Chang, Takashi Nishida, Bo-I Kuo & Jou-Wei Lin. (2021) Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials. Graefe's Archive for Clinical and Experimental Ophthalmology 260:3, pages 937-948.
Crossref
Crossref
NateS Goergen, Meghal Gagrani, Vikas Gulati & Deepta Ghate. (2022) Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center. Indian Journal of Ophthalmology 70:8, pages 2906.
Crossref
Crossref
Olmo Martín-Cámara, Ángel Cores, Pilar López-Alvarado & J. Carlos Menéndez. (2021) Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway. European Journal of Medicinal Chemistry 225, pages 113742.
Crossref
Crossref
Mansi Batra, Sumeet Gupta, Anroop B Nair, Meenakshi Dhanawat, Suraj Sandal & Mohamed Aly Morsy. (2021) Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. European Journal of Ophthalmology 31:5, pages 2237-2244.
Crossref
Crossref
Maria Luísa da Silveira Hahmeyer & José Eduardo da Silva-Santos. (2021) Rho-Proteins and Downstream Pathways as Potential Targets in Sepsis and Septic Shock: What Have We Learned from Basic Research. Cells 10:8, pages 1844.
Crossref
Crossref
C. Erb & K. Konieczka. (2021) Rho-Kinase-Hemmer als neue lokale Therapieoption beim primären OffenwinkelglaukomRho kinase inhibitors as new local therapy option in primary open angle glaucoma. Der Ophthalmologe 118:5, pages 449-460.
Crossref
Crossref
Haiyan Li, Tyler Bagué, Alexander Kirschner, Ana N. Strat, Haven Roberts, Robert W. Weisenthal, Alison E. Patteson, Nasim Annabi, W. Daniel Stamer, Preethi S. Ganapathy & Samuel Herberg. (2021) A tissue-engineered human trabecular meshwork hydrogel for advanced glaucoma disease modeling. Experimental Eye Research 205, pages 108472.
Crossref
Crossref
Ha Min Kim, Ann Q. Tran, Cameron Yang & Lora R. Dagi Glass. (2021) Netarsudil-related Eyelid Wound Dehiscence. Journal of Glaucoma 30:2, pages 206-208.
Crossref
Crossref
Thomas Mundorf, Francis Mah, Huan Sheng & Theresa Heah. (2020) Effects of Netarsudil on the Corneal Endothelium. Ophthalmology Glaucoma 3:6, pages 421-425.
Crossref
Crossref
C. Ellis Wisely, Huan Sheng, Theresa Heah & Terry Kim. (2020) Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2. Advances in Therapy 37:3, pages 1114-1123.
Crossref
Crossref
Nikki A. Mehran, Sapna Sinha & Reza Razeghinejad. (2019) New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye 34:1, pages 72-88.
Crossref
Crossref
Yuou Teng, Kui Lu, Qian Zhang, Lianbo Zhao, Yuna Huang, Angela Maria Ingarra, Hervé Galons, Tingshen Li, Shanshan Cui, Peng Yu & Nassima Oumata. (2019) Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry 183, pages 111641.
Crossref
Crossref
Pimpiroon Ploysangam & Sangita P. Patel. (2019) A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy. Case Reports in Ophthalmological Medicine 2019, pages 1-7.
Crossref
Crossref
Lisa V. Stottlemyer & Robert S. Duszak. 2019. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
549
558
.